Pay in 4 interest-free payments of $7.21 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
BPC-157 is still in experimental stages in veterinary medicine, and is not recognized as a standard approved treatment to dogs
In dietinduced obese mice, NNMTi treatment significantly reduced liver weight, liver volume, and hepatic triglyceride levels, alleviated hepatic steatosis and inflammatory infiltration, downregulated inflammatory factors (such as TNF and IL6) and lipogenic genes (such as FAS), and upregulated lipolytic genes (such as ATGL) in the liver
GHK-Cu (except for injectable routes of administration) goes back into Category 1
Intended only for in-vitro research, such as Receptor-ligand binding studies, Enzyme activity assays, Cell proliferation assays, Cell signaling assays, Epitope mapping, etc
Fast ship Anonymous Rated 5 out of 5 So far the project results speak volumes for the product
Gordon"
